0.000USD0.000åå ŽååŒÂ 07/24, 09:30 (ET)
104.13BæäŸ¡ç·é¡
12.06çŽè¿12ã¶æPER
äž»èŠããŒã¿
43.030å§å€
43.505é«å€
1.91Måºæ¥é«
12.06çŽè¿12ã¶æPER
8.47äºæ³PER
5.120çŽè¿12ã¶æé
åœ
0.08%売買å転ç
43.790忥çµå€
42.900å®å€
56.47M売買代é
17.32æ ªäŸ¡åçç
1.24PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
11.80%çŽè¿12ã¶æé
åœå©åã
3.90%ç·è³ç£å©çç
52.68052é±é«å€
0.51åºæ¥é«æ¯ç%
6.01BçŽå©ç
2.40Bæ ªåŒæ°
3.59591æ ªåœããå©çïŒEPSïŒ
0.32ããŒã¿å€
6.87%èªå·±è³æ¬å©çç
42.32552é±å®å€
1.38%æ¯ãå¹
67.33%ç²å©çç
104.13BæäŸ¡ç·é¡
6.04ãªã¹ã¯ãªã¿ãŒã³
0.98%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-23 äž»èŠã€ã³ãµã€ã
Sanofi SAã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»è¬åæ¥çã§ã®é äœã¯155äž53äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯56.27ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯å®å®æšç§»ãšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Sanofi SAã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Sanofi SAã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Sanofi SA ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ææšî
ææš
売ã(3)
äžç«(2)
è²·ã(1)
ç§»åå¹³å
売ã(5)
äžç«(0)
è²·ã(1)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Sanofi SAã®äŒæ¥æ
å ±î
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofiâs Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Companyâs products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
äŒæ¥ã³ãŒãSNY
äŒæ¥åSanofi SA
æé«çµå¶è²¬ä»»è
ãCEOãHudson (Paul)
ãŠã§ããµã€ãhttps://www.sanofi.com/
æ ªäž»çµ±èšî
ãããã質å
Sanofi SAïŒSNYïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îSanofi SAïŒSNYïŒã®çŸåšã®æ ªäŸ¡ã¯43.38ã§ãã
Sanofi SAã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îSanofi SAã®ãã£ãã«ãŒã·ã³ãã«ã¯SNYã§ãã
Sanofi SAã®52é±é«å€ã¯ãããã§ããïŒ
îSanofi SAã®52é±é«å€ã¯52.68ã§ãã
Sanofi SAã®52é±å®å€ã¯ãããã§ããïŒ
îSanofi SAã®52é±å®å€ã¯42.33ã§ãã
Sanofi SAã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îSanofi SAã®æäŸ¡ç·é¡ã¯104.13Bã§ãã
Sanofi SA (SNY) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãSanofi SAïŒSNYïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯56.27ã§ãã
Sanofi SA (SNY) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îSanofi SAïŒSNYïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯3.61ã§ãã